172 related articles for article (PubMed ID: 11958577)
1. Cyclophosphamide type I hypersensitivity in systemic lupus erythematosus.
Thong BY; Leong KP; Thumboo J; Koh ET; Tang CY
Lupus; 2002; 11(2):127-9. PubMed ID: 11958577
[TBL] [Abstract][Full Text] [Related]
2. Severe infections in plasmapheresis-treated systemic lupus erythematosus.
Aringer M; Smolen JS; Graninger WB
Arthritis Rheum; 1998 Mar; 41(3):414-20. PubMed ID: 9506568
[TBL] [Abstract][Full Text] [Related]
3. Late-onset anaphylactic reactions following i.v. cyclophosphamide pulse in a patient with systemic sclerosis and systemic lupus erythematosus overlap syndrome.
Taniguchi T; Asano Y; Tamaki Z; Takahashi T; Ichimura Y; Toyama T; Kagami S; Mitsui H; Sato S
J Dermatol; 2014 Oct; 41(10):912-4. PubMed ID: 25227247
[TBL] [Abstract][Full Text] [Related]
4. Zoster after Cyclophosphamide for Systemic Lupus Erythematosus or Vasculitis: Incidence, Risk Factors, and Effect of Antiviral Prophylaxis.
Garnier C; Ribes D; Chauveau D; Huart A; Pugnet G; Adoue D; Prevot G; Alric L; Delobel P; Derumeaux H; Mengelle C; Sailler L; Moulis G
J Rheumatol; 2018 Nov; 45(11):1541-1548. PubMed ID: 30008461
[TBL] [Abstract][Full Text] [Related]
5. Severe multiorganic flare of systemic lupus erythematosus successfully treated with rituximab and cyclophosphamide avoiding high doses of prednisone.
Gonzalez-Echavarri C; Pernas B; Ugarte A; Ruiz-Irastorza G
Lupus; 2014 Mar; 23(3):323-6. PubMed ID: 24531426
[TBL] [Abstract][Full Text] [Related]
6. Ovarian function is preserved in women with severe systemic lupus erythematosus after a 6-month course of cyclophosphamide followed by mycophenolate mofetil.
Laskari K; Zintzaras E; Tzioufas AG
Clin Exp Rheumatol; 2010; 28(1):83-6. PubMed ID: 20346244
[TBL] [Abstract][Full Text] [Related]
7. Brief Report: The Euro-Lupus Low-Dose Intravenous Cyclophosphamide Regimen Does Not Impact the Ovarian Reserve, as Measured by Serum Levels of Anti-Müllerian Hormone.
Tamirou F; Husson SN; Gruson D; Debiève F; Lauwerys BR; Houssiau FA
Arthritis Rheumatol; 2017 Jun; 69(6):1267-1271. PubMed ID: 28235250
[TBL] [Abstract][Full Text] [Related]
8. [A multicenter study on the tolerance of intravenous low-dose cyclophosphamide in systemic lupus erythematosus].
Shao M; Guo HF; Lei LY; Zhao Q; Ding YJ; Lin J; Wu R; Yu F; Li YC; Miao HL; Zhang LY; DU Y; Jiao RY; Pang LX; Long L; Li ZG; Li R
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Dec; 54(6):1112-1116. PubMed ID: 36533341
[TBL] [Abstract][Full Text] [Related]
9. Update on cyclophosphamide for systemic lupus erythematosus.
Ortmann RA; Klippel JH
Rheum Dis Clin North Am; 2000 May; 26(2):363-75, vii. PubMed ID: 10768217
[TBL] [Abstract][Full Text] [Related]
10. Anti-müllerian hormone and ovarian reserve in systemic lupus erythematosus.
Mok CC; Chan PT; To CH
Arthritis Rheum; 2013 Jan; 65(1):206-10. PubMed ID: 23044647
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus.
Singh G; Saxena N; Aggarwal A; Misra R
J Rheumatol; 2007 Apr; 34(4):731-3. PubMed ID: 17407229
[TBL] [Abstract][Full Text] [Related]
12. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus.
Somers EC; Marder W; Christman GM; Ognenovski V; McCune WJ
Arthritis Rheum; 2005 Sep; 52(9):2761-7. PubMed ID: 16142702
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in systemic lupus erythematosus (SLE) with oral cyclophosphamide.
Jasmin R; Sockalingam S; Shahrizaila N; Cheah TE; Zain AA; Goh KJ
Lupus; 2012 Sep; 21(10):1119-23. PubMed ID: 22433918
[TBL] [Abstract][Full Text] [Related]
14. [Cyclophosphamide induced amenorrhoea in pre-menopausal women with systemic lupus erythematosus].
Cunha I; Saavedra MJ; Pereira da Silva JA; Malcata A
Acta Reumatol Port; 2008; 33(1):69-76. PubMed ID: 18344924
[TBL] [Abstract][Full Text] [Related]
15. Trends of anticardiolipin antibodies after low-dose methylprednisolone and cyclophosphamide treatment of systemic lupus erythematosus.
Lavalle-Graef A; Villegas-Acosta L; Lavalle C
Arch Med Res; 2004; 35(5):421-7. PubMed ID: 15610913
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus.
Fassbinder T; Saunders U; Mickholz E; Jung E; Becker H; Schlüter B; Jacobi AM
Arthritis Res Ther; 2015 Apr; 17(1):92. PubMed ID: 25890338
[TBL] [Abstract][Full Text] [Related]
17. Ovarian protection with gonadotropin-releasing hormone agonists during cyclophosphamide therapy in systemic lupus erythematosus.
Kado R; McCune WJ
Best Pract Res Clin Obstet Gynaecol; 2020 Apr; 64():97-106. PubMed ID: 31866283
[TBL] [Abstract][Full Text] [Related]
18. Fertility, ovarian failure, and pregnancy outcome in SLE patients treated with intravenous cyclophosphamide in Saudi Arabia.
Alarfaj AS; Khalil N
Clin Rheumatol; 2014 Dec; 33(12):1731-6. PubMed ID: 24894105
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of antiphospholipid antibodies following cyclophosphamide therapy in patients with systemic lupus erythematosus.
Vlachoyiannopoulos PG; Toya SP; Katsifis G; Zintzaras E; Tzioufas AG; Moutsopoulos HM
J Rheumatol; 2008 Sep; 35(9):1768-75. PubMed ID: 18634157
[TBL] [Abstract][Full Text] [Related]
20. Cyclophosphamide-induced severe acute hepatitis in a rheumatic disease: case-based review.
Üsküdar Cansu D; Öztaş E; Yilmaz E; Korkmaz C
Rheumatol Int; 2019 Feb; 39(2):377-385. PubMed ID: 30377772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
